BACKGROUND: We assessed factors associated with antiretroviral therapy (ART) adherence, including specific ART medications. METHODS: The Strategies for Management of Antiretroviral Therapy study was an international antiretroviral therapy (ART) strategy trial that compared intermittent ART, using CD4(+) T-cell count as a guide, to continuous ART. Adherence during the 7 days before each visit was measured using self-report. We defined high adherence as self-report of taking "all" pills for each prescribed ART medication; all other reports were defined as suboptimal adherence. Factors associated with adherence were assessed using logistic regression with generalized estimating equations. RESULTS: Participants reported suboptimal adherence at 6016 of 35 695 study visits (17%). Factors independently associated with suboptimal adherence were black race, protease inhibitor-containing regimens, greater pill burden, higher maximum number of doses per day, and smoking. Factors independently associated with higher adherence were older age, higher education, region of residence, episodic treatment, higher latest (at the time of adherence) CD4(+) T-cell count, and being prescribed concomitant drugs (ie, medications for comorbidities). Of specific drugs investigated, atazanavir, atazanavir/ritonavir, fosamprenavir, indinavir, indinavir/ritonavir, and lopinavir/ritonavir were associated with suboptimal adherence, and tenofovir disoproxil fumarate/emtricitabine was associated with higher adherence. CONCLUSIONS: In this, the largest analysis of ART adherence to date, some protease inhibitor-containing regimens and regimens with >1 dose per day were associated with suboptimal adherence.
RCT Entities:
BACKGROUND: We assessed factors associated with antiretroviral therapy (ART) adherence, including specific ART medications. METHODS: The Strategies for Management of Antiretroviral Therapy study was an international antiretroviral therapy (ART) strategy trial that compared intermittent ART, using CD4(+) T-cell count as a guide, to continuous ART. Adherence during the 7 days before each visit was measured using self-report. We defined high adherence as self-report of taking "all" pills for each prescribed ART medication; all other reports were defined as suboptimal adherence. Factors associated with adherence were assessed using logistic regression with generalized estimating equations. RESULTS:Participants reported suboptimal adherence at 6016 of 35 695 study visits (17%). Factors independently associated with suboptimal adherence were black race, protease inhibitor-containing regimens, greater pill burden, higher maximum number of doses per day, and smoking. Factors independently associated with higher adherence were older age, higher education, region of residence, episodic treatment, higher latest (at the time of adherence) CD4(+) T-cell count, and being prescribed concomitant drugs (ie, medications for comorbidities). Of specific drugs investigated, atazanavir, atazanavir/ritonavir, fosamprenavir, indinavir, indinavir/ritonavir, and lopinavir/ritonavir were associated with suboptimal adherence, and tenofovir disoproxil fumarate/emtricitabine was associated with higher adherence. CONCLUSIONS: In this, the largest analysis of ART adherence to date, some protease inhibitor-containing regimens and regimens with >1 dose per day were associated with suboptimal adherence.
Entities:
Keywords:
HIV infection; adherence; antiretroviral drugs; self-report
Authors: Valentina Cambiano; Fiona C Lampe; Alison J Rodger; Colette J Smith; Anna M Geretti; Rebecca K Lodwick; Dewi I Puradiredja; Margaret Johnson; Leonie Swaden; Andrew N Phillips Journal: AIDS Date: 2010-05-15 Impact factor: 4.177
Authors: C Holkmann Olsen; A Mocroft; O Kirk; S Vella; A Blaxhult; N Clumeck; M Fisher; C Katlama; A N Phillips; J D Lundgren Journal: HIV Med Date: 2007-03 Impact factor: 3.180
Authors: V Cambiano; F C Lampe; A J Rodger; C J Smith; A M Geretti; R K Lodwick; J Holloway; M Johnson; A N Phillips Journal: HIV Med Date: 2009-12-03 Impact factor: 3.180
Authors: A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren Journal: Lancet Date: 1998-11-28 Impact factor: 79.321
Authors: Viviane D Lima; Richard Harrigan; David R Bangsberg; Robert S Hogg; Robert Gross; Benita Yip; Julio S G Montaner Journal: J Acquir Immune Defic Syndr Date: 2009-04-15 Impact factor: 3.731
Authors: M Martin; E Del Cacho; C Codina; M Tuset; E De Lazzari; J Mallolas; J-M Miró; J M Gatell; J Ribas Journal: AIDS Res Hum Retroviruses Date: 2008-10 Impact factor: 2.205
Authors: V E Stone; J Clarke; J Lovell; K A Steger; L R Hirschhorn; S Boswell; A D Monroe; M D Stein; T J Tyree; K H Mayer Journal: J Gen Intern Med Date: 1998-09 Impact factor: 5.128
Authors: David P Sheppard; Erica Weber; Kaitlin B Casaletto; Gunes Avci; Steven Paul Woods Journal: J Assoc Nurses AIDS Care Date: 2016-04-06 Impact factor: 1.354
Authors: Andrew Tomita; Suvira Ramlall; Thirusha Naidu; Sbusisiwe Sandra Mthembu; Nesri Padayatchi; Jonathan K Burns Journal: J Nerv Ment Dis Date: 2019-04 Impact factor: 2.254
Authors: Vinay K Cheruvu; Robert P Igo; Richard J Jurevic; David Serre; Peter A Zimmerman; Benigno Rodriguez; Rajeev K Mehlotra Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Yuehan Zhang; Tracey E Wilson; Adebola Adedimeji; Daniel Merenstein; Joel Milam; Jennifer Cohen; Mardge Cohen; Elizabeth T Golub Journal: AIDS Behav Date: 2018-03
Authors: Danielle C Ompad; Molly Kingdon; Sandra Kupprat; Sophia N Halkitis; Erik David Storholm; Perry N Halkitis Journal: Behav Med Date: 2014 Impact factor: 3.104